N
Nicolas Meyer
Researcher at University of Toulouse
Publications - 292
Citations - 12326
Nicolas Meyer is an academic researcher from University of Toulouse. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 38, co-authored 251 publications receiving 9347 citations. Previous affiliations of Nicolas Meyer include Institut Gustave Roussy & Paul Sabatier University.
Papers
More filters
Journal ArticleDOI
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Michael A. Postow,Jason Chesney,Anna C. Pavlick,Caroline Robert,Kenneth F. Grossmann,David F. McDermott,Gerald P. Linette,Nicolas Meyer,Jeffrey K. Giguere,Sanjiv S. Agarwala,Montaser Shaheen,Marc S. Ernstoff,David R. Minor,April K.S. Salama,Matthew H. Taylor,Patrick A. Ott,Linda Rollin,Christine Horak,Paul Gagnier,Jedd D. Wolchok,F. Stephen Hodi +20 more
TL;DR: The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipILimumab monotherapy.
Journal ArticleDOI
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber,Mario Mandalà,Michele Del Vecchio,Helen Gogas,Ana Arance,C. Lance Cowey,Stéphane Dalle,Michael Schenker,Vanna Chiarion-Sileni,Ivan Marquez-Rodas,Jean-Jacques Grob,Marcus O. Butler,Mark R. Middleton,Michele Maio,Victoria Atkinson,Paola Queirolo,Rene Gonzalez,Ragini R. Kudchadkar,Michael Smylie,Nicolas Meyer,Laurent Mortier,Michael B. Atkins,Georgina V. Long,Shailender Bhatia,Céleste Lebbé,Piotr Rutkowski,Kenji Yokota,Naoya Yamazaki,Tae M. Kim,Veerle de Pril,J Sabater,Anila Qureshi,James Larkin,Paolo A. Ascierto +33 more
TL;DR: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence‐free survival and a lower rate of grade 3 or 4 adverse events than adjuant therapy with ipilimumab.
Journal ArticleDOI
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi,Jason Chesney,Anna C. Pavlick,Caroline Robert,Kenneth F. Grossmann,David F. McDermott,Gerald P. Linette,Nicolas Meyer,Jeffrey K. Giguere,Sanjiv S. Agarwala,Montaser Shaheen,Marc S. Ernstoff,David R. Minor,April K.S. Salama,Matthew H. Taylor,Patrick A. Ott,Christine Horak,Paul Gagnier,Joel Jiang,Jedd D. Wolchok,Michael A. Postow +20 more
TL;DR: 2-year overall survival data from a randomised controlled trial assessing this treatment in previously untreated advanced melanoma and the proportion of patients with BRAFV600 wild-type melanoma achieving an investigator-assessed objective response is reported.
Journal ArticleDOI
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies,Philippe Saiag,Caroline Robert,Jean-Jacques Grob,Keith T. Flaherty,Ana Arance,Vanna Chiarion-Sileni,Luc Thomas,Thierry Lesimple,Laurent Mortier,Stergios J. Moschos,David Hogg,Ivan Marquez-Rodas,Michele Del Vecchio,Céleste Lebbé,Nicolas Meyer,Ying Zhang,Yingjie Huang,Bijoyesh Mookerjee,Georgina V. Long +19 more
TL;DR: Results from the phase 2 COMBI-MB trial provide evidence of clinical benefit with dabrafenib plus trametinib and support the need for additional research to further improve outcomes in patients with melanoma brain metastases.
Journal ArticleDOI
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
Corine Bertolotto,Fabienne Lesueur,Sandy Giuliano,Thomas Strub,Mahaut de Lichy,Karine Bille,Philippe Dessen,Benoit d’Hayer,Hamida Mohamdi,Audrey Remenieras,Eve Maubec,Arnaud de la Fouchardière,Vincent Molinié,Pierre Vabres,Stéphane Dalle,N. Poulalhon,Tanguy Martin-Denavit,Luc Thomas,Pascale Andry-Benzaquen,Nicolas Dupin,F. Boitier,Annick Rossi,Jean-Luc Perrot,Bruno Labeille,Caroline Robert,Bernard Escudier,Olivier Caron,Laurence Brugières,Simon Saule,Betty Gardie,Sophie Gad,Stéphane Richard,Jérôme Couturier,Bin Tean Teh,Paola Ghiorzo,Lorenza Pastorino,Susana Puig,Celia Badenas,Håkan Olsson,Christian Ingvar,Etienne Rouleau,Rosette Lidereau,Philippe Bahadoran,Philippe Vielh,Eve Corda,Hélène Blanché,Diana Zelenika,Pilar Galan,François Aubin,Bertrand Bachollet,Celine Becuwe,Pascaline Berthet,Yves-Jean Bignon,Valérie Bonadona,Jean -Louis Bonafe,Marie -Noelle Bonnet-Dupeyron,Frédéric Cambazard,Jacqueline Chevrant-Breton,Isabelle Coupier,Sophie Dalac,Liliane Demange,Michel D'Incan,Catherine Dugast,Laurence Faivre,Lynda Vincent-Fetita,Marion Gauthier-Villars,Brigitte Gilbert,Florent Grange,Jean-Jacques Grob,Philippe Humbert,Nicolas Janin,Pascal Joly,Delphine Kerob,Christine Lasset,Dominique Leroux,Julien Levang,Jean -Marc Limacher,Cristina Bulai Livideanu,Michel Longy,Alain Lortholary,Dominique Stoppa-Lyonnet,Sandrine Mansard,Ludovic Mansuy,Karine Marrou,Christine Mateus,Christine Maugard,Nicolas Meyer,Catherine Noguès,Pierre Souteyrand,Laurence Venat-Bouvet,Hélène Zattara,Valérie Chaudru,Gilbert M. Lenoir,Mark Lathrop,Irwin Davidson,Marie-Françoise Avril,Florence Demenais,Robert Ballotti,Brigitte Bressac-de Paillerets +98 more
TL;DR: A germline missense substitution in MITF (Mi-E318K) is identified that occurred at a significantly higher frequency in genetically enriched patients affected with melanoma, RCC or both cancers, when compared with controls and provides insights into the link between SUMOylation, transcription and cancer.